drug
SOLIQUA 100/33
updated 3mo agoby Sanofi-Aventis US LLC
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval48 co-mentions · 12 sources
- druginsulin glargine LA24 co-mentions · 12 sources
- company$SNYSanofi24 co-mentions · 12 sources
- company$SNYNFSanofi24 co-mentions · 12 sources
- companySanofi-Aventis US LLC24 co-mentions · 12 sources
- drugToujeo LA24 co-mentions · 12 sources
- drug(insulin glargine + lixisenatide)24 co-mentions · 12 sources
- drugAbasaglar24 co-mentions · 12 sources
all catalysts(0)
nothing on the calendar yet
Trials studying SOLIQUA 100/33
- phase4A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
- phase3A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- phase3A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- phase3A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- phase3A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
- phase4iGlarLixi CGM Study in Chinese T2D Individuals After OADs
- phase3A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
News(4)
- STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and moreSeven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 eachstat · 1d ago
- STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and moreIn a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugsstat · 21d ago
- A new, separate outbreak of the diarrhea-causing parasiteA win for peptide proponents, autism advisory committees clash, and more health news from Morning Roundsstat · 21d ago
- STAT+: Popular insulin product enters shortage as other pens leave marketThe Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.stat · 22d ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that